Nanomedicine: towards development of patient-friendly drug-delivery systems for oncological applications

被引：152

作者：

Ranganathan, Ramya ^{[1
]}

Madanmohan, Shruthilaya ^{[1
]}

Kesavan, Akila ^{[1
]}

Baskar, Ganga ^{[1
]}

Krishnamoorthy, Yoganathan Ramia ^{[2
]}

Santosham, Roy ^{[3
]}

Ponraju, D. ^{[4
]}

Rayala, Suresh Kumar ^{[2
]}

Venkatraman, Ganesh ^{[1
]}

机构：

[1] Sri Ramachandra Univ, Dept Human Genet, Madras 600116, Tamil Nadu, India

[2] Indian Inst Technol, Dept Biotechnol, Madras 600036, Tamil Nadu, India

[3] Sri Ramachandra Univ, Dept Radiol & Imaging Sci, Madras 600116, Tamil Nadu, India

[4] Indira Gandhi Ctr Atom Res, Safety Engn Div, Nucl & Engn Safety Grp, Kalpakkam 603102, Tamil Nadu, India

来源：

INTERNATIONAL JOURNAL OF NANOMEDICINE | 2012年 / 7卷

关键词：

patient-friendly; drug-delivery systems; cancer; nanomedicine; POLYETHYLENE-GLYCOL-LIPOSOMES; FOLATE-RECEPTOR; IN-VITRO; CYANOACRYLATE) NANOPARTICLES; MAGNETIC NANOPARTICLES; CLINICAL-APPLICATIONS; ANTITUMOR-ACTIVITY; TARGETED DELIVERY; CANCER CELLS; IRON-OXIDE;

D O I：

10.2147/IJN.S25182

中图分类号：

TB3 [工程材料学];

学科分类号：

082905 [生物质能源与材料];

摘要：

The focus on nanotechnology in cancer treatment and diagnosis has intensified due to the serious side effects caused by anticancer agents as a result of their cytotoxic actions on normal cells. This nonspecific action of chemotherapy has awakened a need for formulations capable of definitive targeting with enhanced tumor-killing. Nanooncology, the application of nanobiotechnology to the management of cancer, is currently the most important area of nanomedicine. Currently several nanomaterial-based drug-delivery systems are in vogue and several others are in various stages of development. Tumor-targeted drug-delivery systems are envisioned as magic bullets for cancer therapy and several groups are working globally for development of robust systems.

引用

页码：1043 / 1060

页数：18

共 75 条

[1]

Biodistribution of polysorbate 80-coated doxorubicin-loaded [14C]-poly(butyl cyanoacrylate) nanoparticles after intravenous administration to glioblastoma-bearing rats [J].